$BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Healthcare
Sector
Biotechnology
Industry
Peter A. Altman
CEO
17
Employees
$1.04
Current Price
$6.32M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 1 | 2 | $475.00 | 500 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 3 | $1,505.00 | 1,500 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 1 | 5 | $4,372.00 | 4,200 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 1 | 8 | $15,042.00 | 16,500 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Oct 16, 2026 | Altman Peter Director | Purchase | 300 | $0.95 | $285.00 | View Details |
| Oct 15, 2026 | Altman Peter Director | Purchase | 200 | $0.95 | $190.00 | View Details |
| Sep 29, 2026 | Altman Peter Director | Purchase | 1,000 | $1.03 | $1,030.00 | View Details |
| Sep 23, 2026 | Altman Peter Director | Purchase | 1,900 | $1.05 | $1,995.00 | View Details |
| Sep 3, 2026 | Altman Peter Director | Purchase | 800 | $1.09 | $872.00 | View Details |
| Aug 17, 2026 | Altman Peter Director | Purchase | 5,400 | $0.93 | $5,022.00 | View Details |
| Aug 13, 2026 | Altman Peter Director | Purchase | 1,900 | $0.92 | $1,748.00 | View Details |
| Jul 29, 2026 | Altman Peter Director | Purchase | 5,000 | $0.78 | $3,900.00 | View Details |
26 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.15
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.